Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

ketamine

Science

13 Oct 2023

FDA Issues Warning Letter for Ketamine

The FDA has issued a warning letter regarding the use of ketamine outside of FDA-approved conditions....

By Jason Najum
mushroom rats

Science

11 Oct 2023

New Study Shows Microdoses Reduce Compulsive Behavior (in rats)

A new study in rodents shows that low doses of psilocybin increase resilience to stress and lower compulsive actions....

By Jason Najum

Breaking News, Law & Politics

8 Oct 2023

Breaking News: California Governor Vetoes Psychedelics Decriminalization Bill

California governor has vetoed a major psychedelic decrim bill, but supports a comprehensive law that establishes guidelines for regulated therapeutic access....

By Jason Najum

Science

6 Oct 2023

New Study Shows Spravato Effective When Combined With SSRIs

A new study published in the New England Journal of Medicine found that Spravato’s esketamine was more effective than a commonly prescribed drug in treating treatment-resistant depression....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

29 Sep 2023

Canadian Military Veteran Receives Approval for Psilocybin Therapy

Health Canada has granted permission for a Canadian military veteran to receive much-needed psilocybin therapy....

By Jason Najum
pills

Science

26 Sep 2023

Positive Data from Small Pharma’s New Study Combining DMT & SSRIs

Topline results from Small Pharma's Phase Ib study exploring the interaction between SSRIs and SPL026, the company’s DMT drug....

By Jason Najum

Finance

18 Sep 2023

Billionaire Investor Steve Cohen Buys 19 million Shares of Cybin

Renowned billionaire investor Steve Cohen has purchased almost 19 million shares of Cybin....

By Jason Najum
ketamine

Breaking News

6 Sep 2023

PharmaTher Submits New Drug Application to the FDA

Will PharmaTher be the next company to get a psychedelic medicine to market?...

By Jason Najum
mushrooms

Science

31 Aug 2023

New Johns Hopkins Study Shows Psilocybin Helps Long Term Mental Health

A new study from Johns Hopkins shows that psilocybin use promotes positive long-term effects on well-being....

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.